Document Type

Article

Publication Date

9-17-2020

Publication Title

Journal of the American Academy of Dermatology

Abstract

BACKGROUND: Topical psoriasis treatment relies on a reactive, rather than long-term proactive, approach to disease relapse.

OBJECTIVE: Assess long-term efficacy and safety of proactive psoriasis management with twice-weekly calcipotriene 0.005%/betamethasone dipropionate 0.064% (Cal/BD) foam.

METHODS: Phase III trial (NCT02899962) included a 4-week open-label lead-in phase (Cal/BD foam once-daily) and 52-week, randomized, double-blind, maintenance phase. 545 patients achieved treatment success PGA 'clear'/'almost clear', ≥2-grade improvement from baseline) and were randomized to 'proactive' management (Cal/BD foam; n = 272) or 'reactive' management (vehicle foam; n = 273) twice-weekly, with rescue treatment of Cal/BD foam once-daily for 4 weeks upon relapse. Primary endpoint: time to first relapse (PGA ≥'mild').

RESULTS: 251 (46.1%) randomized patients completed the trial. Median time to first relapse: 56 days (proactive), 30 days (reactive). Patients in the proactive group had an additional 41 days in remission compared with the reactive group over 1 year (P < 0.001). Number of relapses per year of exposure: 3.1 (proactive), 4.8 (reactive). Cal/BD foam was well tolerated.

LIMITATIONS: Maintenance phase dropout rate (53.9%) was within the expected range but provides challenges in statistical analysis.

CONCLUSION: Long-term proactive management with Cal/BD foam demonstrated superior efficacy versus reactive management.

PubMed ID

32950546

ePublication

ePub ahead of print

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.